Article Details

Indian Biotech Firm Develops World's First, Indigenous Bi-Specific 3rd Generation CAR T ...

Retrieved on: 2025-03-24 12:48:19

Tags for this article:

Click the tags to see associated articles and topics

Indian Biotech Firm Develops World's First, Indigenous Bi-Specific 3rd Generation CAR T .... View article details on hiswai:

Summary

The article details Indian biotech startup Cellogen Therapeutics' achievement in developing bispecific 3rd-generation CAR T cell therapy, a significant advancement in cancer immunotherapy. This relates to the key concept 'Biotech' and various tags by highlighting India's growing role in innovative cancer treatment, aligning with global biotechnology developments.

Article found on: startupnews.fyi

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo